Candida krusei

The at‑home Candida krusei test detects and identifies the presence of Candida krusei — a yeast species that can cause vulvovaginal candidiasis or contribute to urinary tract infections — using laboratory methods (culture and/or molecular assays) performed at accredited diagnostic labs. Species-level identification is important because C. krusei often shows intrinsic resistance to common antifungals such as fluconazole, so accurate detection helps clinicians choose effective treatment.

This service provides discreet sample collection from home across Dubai and the UAE, secure lab-certified reporting, and rapid turnaround to support timely clinical decisions. The test is suitable for people with recurrent or persistent yeast symptoms, those with UTI-like complaints unresponsive to antibiotics, immunocompromised patients, or anyone whose infection did not improve after prior antifungal therapy; consult your healthcare provider to interpret results and plan treatment in the UAE clinical context.

• Candida krusei detection
• Candida species identification
• Fungal culture / PCR result
• Semi‑quantitative fungal load (CFU/ml)
• Antifungal susceptibility profile (where available)

• Recurrent or persistent vaginal yeast infections
• Burning, itching, or abnormal genital discharge
• Urinary symptoms not improving with standard antibiotics
• Infection persisting after antifungal treatment
• Immunocompromised individuals or people with diabetes with persistent symptoms

• Discreet at‑home sample collection across Dubai and the UAE
• Laboratory‑certified, species‑level identification to guide therapy
• Rapid turnaround and secure online reporting for timely care
• Helps avoid ineffective antifungals by identifying resistant species
• Clinical interpretation support recommended to coordinate treatment in UAE healthcare settings

• Sample: midstream urine or vaginal swab (as instructed in the kit)
• Avoid sexual intercourse, douching, or vaginal medications for 24–48 hours before sampling
• Avoid starting systemic antifungals or antibiotics for 48–72 hours prior, if clinically safe and advised by your physician